Executive Director of the Clinical Research Center at Zhujiang Hospital, Southern Medical University; Professor; Doctoral Supervisor.
He is a Specially Appointed Expert under the National Major Talent Program, a Leading Medical Talent of Guangdong Province, and a Leading Scientific and Technological Innovation Talent under the Guangdong "Pearl River Talent Plan."
Current Professional Affiliations:
- Chair of the Research and Education Committee of the International Osteoarthritis Research Society (OARSI) and OARSI Strategic Alliance Committee Ambassador for China;
- Vice President of the International Chinese Osteoarthritis Research Society (ICOARS);
- Vice President of the Australian Chinese Biomedical Association and Chair of its Tasmania Branch;
- Chair of the Tasmania Scholars and Experts Association;
- Honorary Vice Chair of the Rheumatology and Immunology Committee of the Cross-Strait Medical and Health Exchange Association;
- Vice Chair of the Clinical Research Branch of the Guangdong Medical Association;
- Standing Committee Member of the Clinical Pharmacology Committee of the Guangdong Pharmacological Association;
- Secretary-General of the Guangdong Clinical Research Quality Control Center;
- Chair of the Clinical Research Expert Committee of Guangdong Medical Institutions.
Editorial Roles:
- Associate Editor of "Reviews on Recent Clinical Trials";
- Editorial Board Member of 7 international journals, including "Osteoarthritis & Cartilage", "Journal of Orthopaedic Translation", "Arthritis Research & Therapy", and "Nutrients".
Research Achievements:
He has published over 300 SCI papers in international journals such as "JAMA", "JAMA Internal Medicine", "Annals of the Rheumatic Diseases", "Arthritis & Rheumatology", "Radiology", and "Science Translational Medicine". Among these, he has published one research article and three correspondence articles as the first or corresponding author in *JAMA*. In total, he has authored or co-authored over 180 SCI papers as the first or corresponding author, with a cumulative impact factor exceeding 3000.
He has been consecutively listed in Elsevier's "Highly Cited Chinese Researchers" for five years (2019-2023) and has been recognized by Expertscape as one of the top 0.05% of scholars worldwide in the field of osteoarthritis, earning the title of "World Expert in Osteoarthritis." He has also been included in the global top 2% of scientists for lifetime scientific impact for three consecutive years.
